Lampasas
Lampasas
Lampasas, Texas, United States20 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 2 | 2026-10-07 | NCT07668388 | |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Cushing syndrome, Nutritional and Metabolic Diseases, Paraneoplastic Endocrine Syndromes, adrenal gland disorder, adrenal gland hyperfunction, diabetes mellitus, ectopic ACTH secretion syndrome, endocrine system disorder, glucose metabolism disease, metabolic disease, neoplasm, paraneoplastic syndrome, type 2 diabetes mellitus | Recruiting | Phase 2 | 2026-10-06 | NCT07296484 | |
| Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-10-05 | NCT06961214 | |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Recruiting | Phase 3 | 2026-09-30 | NCT07564414 | |
| A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-09-30 | NCT07011667 | |
| Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-24 | NCT07157774 | |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-09-22 | NCT07190209 | |
| Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | brain disorder, central nervous system disorder, headache disorder, hypnic headache, migraine disorder, nervous system disorder | Recruiting | Phase 3 | 2026-09-14 | NCT05125302 | |
| A Study to Assess the Safety, Tolerability and Efficacy of ION775 | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic disease | Recruiting | Phase 2 | 2026-09-03 | NCT07604974 | |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | cardiovascular disorder | Active, not recruiting | Phase 3 | 2026-08-31 | NCT05669755 | |
| A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine | Acute Migraine | Recruiting | Phase 3 | 2026-08-27 | NCT07674654 | |
| Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Active, not recruiting | Phase 3 | 2026-08-25 | NCT05030428 | |
| A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | brain disorder, central nervous system disorder, headache disorder, hypnic headache, migraine disorder, nervous system disorder | Recruiting | Phase 3 | 2026-08-20 | NCT07645924 | |
| Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | brain disorder, central nervous system disorder, headache disorder, hypnic headache, migraine disorder, nervous system disorder | Active, not recruiting | Phase 3 | 2026-08-14 | NCT06417775 | |
| Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Menstruation Disturbances, Neurologic Manifestations, Pain, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pelvic Pain, Signs and Symptoms, Urogenital Diseases, dysmenorrhea, endometriosis, female reproductive system disorder | Active, not recruiting | Phase 3 | 2026-06-12 | NCT04333576 | |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Body Weight, Body Weight Changes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss | Active, not recruiting | Phase 3 | 2026-04-07 | NCT07104383 | |
| CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic disease | Active, not recruiting | Phase 3 | 2025-12-01 | NCT05681351 | |
| VK2735 for Weight Management Phase 3 | Body Weight, Body Weight Changes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss | Active, not recruiting | Phase 3 | 2025-11-24 | NCT07104500 | |
| Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17) | brain disorder, central nervous system disorder, headache disorder, hypnic headache, migraine disorder, nervous system disorder | Enrolling by invitation | Phase 3 | 2025-07-20 | NCT05127954 | |
| Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy | Diabetes Complications, Diabetic Cardiomyopathies, Nutritional and Metabolic Diseases, cardiomyopathy, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, metabolic disease, type 2 diabetes mellitus | Active, not recruiting | Phase 3 | 2022-12-08 | NCT04083339 |